Comparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replacement

Metabolism: Clinical and Experimental

Volumn 59, Issue 3, 2010, Pages 350-358

  Roemmler, Josefine ^a   Kuenkler, Maren ^a   Schneider, Harald J ^a   Dieterle, Christoph ^a   Schopohl, Jochen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; C PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROCORTISONE; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN; METFORMIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BLOOD SAMPLING; BODY COMPOSITION; BODY MASS; BONE DENSITY; BONE MINERALIZATION; CHOLESTEROL BLOOD LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OSTEOPOROSIS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; BODY COMPOSITION; BONE DENSITY; CALCIFICATION, PHYSIOLOGIC; CROSS-SECTIONAL STUDIES; FEMALE; GLUCOSE; HOMEOSTASIS; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 76249093601     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.08.002     Document Type: Article

References (57)

1. Rizza R.A., Mandarino L.J., and Gerich J.E. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31 8 Pt 1 (1982) 663-669
2. Moller N., Jorgensen J.O., Schmitz O., Moller J., Christiansen J., Alberti K.G., et al. Effects of a growth hormone pulse on total and forearm substrate fluxes in humans. Am J Physiol 258 1 Pt 1 (1990) E86-E91
3. Bramnert M., Segerlantz M., Laurila E., Daugaard J.R., Manhem P., and Groop L. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle. J Clin Endocrinol Metab 88 (2003) 1455-1463
4. Johannsson G., Marin P., Lonn L., Ottosson M., Stenlof K., Bjorntorp P., et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82 (1997) 727-734
5. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
6. Bulow B., Link K., Ahren B., Nilsson A.S., and Erfurth E.M. Survivors of childhood acute lymphoblastic leukaemia, with radiation-induced GH deficiency, exhibit hyperleptinaemia and impaired insulin sensitivity, unaffected by 12 months of GH treatment. Clin Endocrinol (Oxf) 61 (2004) 683-691
7. Alford F.P., Hew F.L., Christopher M.C., and Rantzau C. Insulin sensitivity in growth hormone (GH)-deficient adults and effect of GH replacement therapy. J Endocrinol Invest 22 5 Suppl (1999) 28-32
8. Gillberg P., Bramnert M., Thoren M., Werner S., and Johannsson G. Commencing growth hormone replacement in adults with a fixed low dose. Effects on serum lipoproteins, glucose metabolism, body composition, and cardiovascular function. Growth Horm IGF Res 11 5 (2001) 273-281
9. Arwert L.I., Roos J.C., Lips P., Twisk J.W., Manoliu R.A., and Drent M.L. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf) 63 (2005) 310-316
10. Spina L.D., Soares D.V., Brasil R.R., Lobo P.M., Lucia Conceicao F., and Vaisman M. Glucose metabolism and visceral fat in GH deficient adults: two years of GH-replacement. Pituitary 7 (2004) 123-129
11. Chrisoulidou A., Beshyah S.A., Rutherford O., Spinks T.J., Mayet J., Kyd P., et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 85 (2000) 3762-3769
12. Hana V., Silha J.V., Justova V., Lacinova Z., Stepan J.J., and Murphy L.J. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance. Clin Endocrinol (Oxf) 60 (2004) 442-450
13. Hwu C.M., Kwok C.F., Lai T.Y., Shih K.C., Lee T.S., Hsiao L.C., et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 82 (1997) 3285-3292
14. Svensson J., Fowelin J., Landin K., Bengtsson B.A., and Johansson J.O. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab 87 (2002) 2121-2127
15. Yuen K.C., and Dunger D.B. Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults. Growth Horm IGF Res 16 Suppl A (2006) S55-S61
16. Cutfield W.S., Wilton P., Bennmarker H., Albertsson-Wikland K., Chatelain P., Ranke M.B., et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet 355 (2000) 610-613
17. Boguszewski C.L., Meister L.H., Zaninelli D.C., and Radominski R.B. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol 152 (2005) 67-75
18. Eden Engstrom B., Burman P., Holdstock C., and Karlsson F.A. Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J Clin Endocrinol Metab 88 (2003) 5193-5198
19. Spina L.D., Soares D.V., Brasil R.R., da Silva E.M., Lobo P.M., Conceicao F.L., et al. Glucose metabolism and visceral fat in GH deficient adults: 1 year of GH replacement. Growth Horm IGF Res 14 (2004) 45-51
20. Cenci M.C., Conceicao F.L., Soares D.V., Spina L.D., Brasil R.R., Lobo P.M., et al. Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults. Metabolism 57 (2008) 121-129
21. van der Klaauw A.A., Romijn J.A., Biermasz N.R., Smit J.W., van Doorn J., Dekkers O.M., et al. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol 155 (2006) 701-708
22. Gotherstrom G., Svensson J., Koranyi J., Alpsten M., Bosaeus I., Bengtsson B., et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86 (2001) 4657-4665
23. ter Maaten J.C., de Boer H., Kamp O., Stuurman L., and van der Veen E.A. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab 84 (1999) 2373-2380
24. Murray R.D., Adams J.E., and Shalet S.M. A densitometric and morphometric analysis of the skeleton in adults with varying degrees of GH deficiency. J Clin Endocrinol Metab (2005)
25. Clanget C., Seck T., Hinke V., Wuster C., Ziegler R., and Pfeilschifter J. Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin Endocrinol (Oxf) 55 (2001) 93-99
26. Gotherstrom G., Bengtsson B.A., Bosaeus I., Johannsson G., and Svensson J. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol 156 (2007) 55-64
27. Elmlinger M.W., Kuhnel W., Weber M.M., and Ranke M.B. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 42 (2004) 654-664
28. Bristow A.F., Gooding R.P., and Das R.E. The international reference reagent for insulin-like growth factor-I. J Endocrinol 125 (1990) 191-197
29. Wu Z., Bidlingmaier M., Liu C., De Souza E.B., Tschop M., Morrison K.M., et al. Quantification of the soluble leptin receptor in human blood by ligand-mediated immunofunctional assay. J Clin Endocrinol Metab 87 (2002) 2931-2939
30. Matsuda M., and DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999) 1462-1470
31. al-Shoumer K.A., Gray R., Anyaoku V., Hughes C., Beshyah S., Richmond W., et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol (Oxf) 48 (1998) 795-802
32. Fowelin J., Attvall S., Lager I., and Bengtsson B.A. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 42 (1993) 1443-1447
33. Giavoli C., Porretti S., Ronchi C.L., Cappiello V., Ferrante E., Orsi E., et al. Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. Metabolism 53 (2004) 740-743
34. Yuen K.C., and Dunger D.B. Persisting effects on fasting glucose levels and insulin sensitivity after 6 months of discontinuation of a very low-dose GH therapy in adults with severe GH deficiency. Clin Endocrinol (Oxf) 64 (2006) 549-555
35. Yuen K.C., Frystyk J., White D.K., Twickler T.B., Koppeschaar H.P., Harris P.E., et al. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf) 63 (2005) 428-436
36. Yuen K., Cook D., Ong K., Chatelain P., Fryklund L., Gluckman P., et al. The metabolic effects of short-term administration of physiological versus high doses of GH therapy in GH deficient adults. Clin Endocrinol (Oxf) 57 (2002) 333-341
37. Gotherstrom G., Bengtsson B.A., Bosaeus I., Johannsson G., and Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 92 (2007) 1442-1445
38. Bakker I., Twisk J.W., Van Mechelen W., and Kemper H.C. Fat-free body mass is the most important body composition determinant of 10-yr longitudinal development of lumbar bone in adult men and women. J Clin Endocrinol Metab 88 (2003) 2607-2613
39. Fink R.I., Kolterman O.G., Griffin J., and Olefsky J.M. Mechanisms of insulin resistance in aging. J Clin Invest 71 (1983) 1523-1535
40. Attallah H., Friedlander A.L., and Hoffman A.R. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy. Growth Horm IGF Res 16 Suppl A (2006) S62-S67
41. Ketel I.J., Volman M.N., Seidell J.C., Stehouwer C.D., Twisk J.W., and Lambalk C.B. Superiority of skinfold measurements and waist over waist-to-hip ratio for determination of body fat distribution in a population-based cohort of Caucasian Dutch adults. Eur J Endocrinol 156 (2007) 655-661
42. Goodman-Gruen D., and Barrett-Connor E. Sex differences in measures of body fat and body distribution in the elderly. Am J Epidemiol 143 (1996) 898-906
43. Sesmilo G., Biller B.M., Llevadot J., Hayden D., Hanson G., Rifai N., et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 133 (2000) 111-122
44. Gibney J., Wallace J.D., Spinks T., Schnorr L., Ranicar A., Cuneo R.C., et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 84 (1999) 2596-2602
45. Attanasio A.F., Bates P.C., Ho K.K., Webb S.M., Ross R.J., Strasburger C.J., et al. Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition and lipid status-3-year results from the HypoCCS Database. J Clin Endocrinol Metab 87 (2002) 1600-1606
46. Brown C.D., Higgins M., Donato K.A., Rohde F.C., Garrison R., Obarzanek E., et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 8 (2000) 605-619
47. Jung C.H., Lee W.Y., Rhee E.J., Kim S.Y., Oh K.W., Yun E.J., et al. Serum ghrelin and leptin levels in adult growth hormone deficiency syndrome. Arch Med Res 37 (2006) 612-618
48. Miyakawa M., Tsushima T., Murakami H., Isozaki O., Demura H., and Tanaka T. Effect of growth hormone (GH) on serum concentrations of leptin: study in patients with acromegaly and GH deficiency. J Clin Endocrinol Metab 83 (1998) 3476-3479
49. Hansen T.B., Brixen K., Vahl N., Jorgensen J.O., Christiansen J.S., Mosekilde L., et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo-controlled study. J Clin Endocrinol Metab 81 (1996) 3352-3359
50. Johannsson G., Rosen T., Bosaeus I., Sjostrom L., and Bengtsson B.A. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. J Clin Endocrinol Metab 81 (1996) 2865-2873
51. Underwood L.E., Attie K.M., and Baptista J. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 88 (2003) 5273-5280
52. Fernholm R., Bramnert M., Hagg E., Hilding A., Baylink D.J., Mohan S., et al. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J Clin Endocrinol Metab 85 (2000) 4104-4112
53. Gill M.S., Toogood A.A., Jones J., Clayton P.E., and Shalet S.M. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency. J Clin Endocrinol Metab 84 (1999) 1288-1295
54. Kaufman J.M., Taelman P., Vermeulen A., and Vandeweghe M. Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 74 (1992) 118-123
55. Attanasio A.F., Howell S., Bates P.C., Frewer P., Chipman J., Blum W.F., et al. Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. J Clin Endocrinol Metab 87 (2002) 3368-3372
56. Gomez-Ambrosi J., Rodriguez A., Catalan V., and Fruhbeck G. The bone-adipose axis in obesity and weight loss. Obes Surg 18 (2008) 1134-1143
57. Richards J.B., Valdes A.M., Burling K., Perks U.C., and Spector T.D. Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 92 (2007) 1517-1523